Option traders appear to be setting up for a bullish move on CA Technologies (CA). Traders plowed into 4,799 new call option contracts -- 13.87 times the average volume -- on the stock on Thursday. And we know that traders were eager to get into this trade because 98% of the trades came in on the "ask" price.

CA Technologies closed Thursday at $18.13. The stock has dropped 7.64% during the past month, but it is currently sitting at support just above $18.

Continue reading Option Traders Buying CA Technologies Calls and Tibco Puts

Option Traders Buying CA Technologies Calls and Tibco Puts originally appeared on BloggingStocks on Fri, 27 Aug 2010 08:30:00 EST. Please see our terms for use of feeds.

Auxilium Pharmaceuticals (NASDAQ: AUXL) is a specialty biopharmaceutical company with a focus on developing products for urologists, endocrinologists, orthopedists and select primary care physicians. The firm markets Testim, a topical testosterone gel for the treatment of hypogonadism. It also has projects in clinical development for the treatment of Dupuytren's contracture, Peyronie's disease, Frozen Shoulder syndrome and overactive bladder.

The stock is up 48% over the past fifteen weeks, sparked by such issues as better than expected Q3 results, upside guidance and subsequent affirmation of FY07 revenues, and positive clinic trial developments. The news has the stock cycling through a positive trading channel. The price is consolidating at the base of that channel, where oversold CCI, MACD and Stochastic technical parameters suggest the potential for a rise back toward the top. Correspondence of the stock's 30-day moving average to the base of the channel backs the rebound notion.

Continue reading Auxilium Pharmaceuticals: Shares advance through a positive trading channel

Auxilium Pharmaceuticals: Shares advance through a positive trading channel originally appeared on BloggingStocks on Wed, 09 Jan 2008 12:57:00 EST. Please see our terms for use of feeds.